AEON Biopharma Expects $6.2 Million in Gross Proceeds From Warrant Exercises

• AEON Biopharma reduced its Two-Year Warrants’ common stock exercise price to $0.20 from $0.3221, effective November 2, 2026.
• The exercise price for Pre-Funded Warrants fell to $0.1999 from $0.3220.
• Certain holders agreed to exercise at the reduced prices, generating expected gross proceeds of approximately $6.2 million.
• The amendment applies to all outstanding Two-Year Warrants; underlying share counts remain unchanged.
• The warrants expire November 16, 2026, following accelerated expiration triggered by the September 30, 2026, announcement of FDA meeting minutes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AEON Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001837607-26-000081), on November 03, 2026, and is solely responsible for the information contained therein.